Initial Status Conference Set in MDL for Tepezza Hearing Damage Lawsuits

Tepezza hearing damage lawsuits claim the manufacturer failed to warn patients and the medical community that the thyroid eye disease drug could cause hearing loss and tinnitus.

The U.S. District Judge recently appointed to preside over all Tepezza hearing damage lawsuits has scheduled an initial status conference for later this month, at which time the Court will discuss a number protocols and procedures designed to move the rapidly growing litigation forward.

Although Tepezza (teprotumumab-trbw) was just introduced by Horizon Therapeutics in January 2020, as a new-generation biologic treatment for thyroid eye disease and bulging eyes, hundreds of former users are already coming forward to pursue lawsuits after experiencing various hearing side effects from Tepezza, including persistent ringing in the ears known as tinnitus, and complete hearing loss.

The drug was initially expected to only be a niche treatment, with only a limited market. However, following aggressive marketing that suggested the drug was safe and carried few side effects, sales in the U.S. doubled to $1.66 billion in the second year it was on the market, and critics have expressed concern that Horizon failed to adequately disclose the potential risks associated with their drug and the importance of monitoring for hearing damage during Tepezza treatment.

Although there are currently only a handful of claims filed throughout the federal court system, it is widely expected that hundreds, if not thousands of Tepezza hearing damage lawsuits will brought in the coming months and years.

Tepezza Lawsuits

Do You Have Hearing Loss from Tepezza?

Side effects of Tepezza may cause permanent hearing problems. Lawsuits are being pursued over the drug maker's failure to warn about the risk. Find out if qualify for a settlement.


To help manage the claims, which each raise similar questions of fact and laws, a Tepezza MDL (multidistrict litigation) was established earlier this month, centralizing complaints filed throughout the federal court system before U.S. District Judge Thomas Durkin in the Northern District of Illinois for coordinated discovery and pretrial proceedings.

Tepezza Hearing Damage Lawsuits Initial Status Conference

On June 16, Judge Durkin issued a case management order (PDF), providing an early overview of how the cases will be managed in the MDL, and scheduling the first status conference to be held on June 28.

Topics to be addressed at the initial conference include whether consolidated complaints, involving more than one plaintiff who suffered Tepezza hearing damage, will be allowed. It will also cover potential orders the court may issue to preserve evidence, and appointing Tepezza lawyers to leadership positions, who will take certain actions during discovery and pretrial proceedings that benefit all plaintiffs.

Although Judge Durkin noted that the Court does not intend to make final decisions regarding the appointment of attorneys to lead the litigation at the hearing, he said such a decision will come promptly after the conference.

On June 12, a group of Tepezza lawyers filed a motion which proposed a slate of attorneys to serve in leadership positions in the Tepezza MDL. The unopposed motion calls for three attorneys to serve as co-lead counsel- one liaison counsel, and an eight-person executive committee.

As part of the coordinated management of the Tepezza lawsuits, it is expected that Judge Durkin will also eventually establish a “bellwether” program, where a small group of representative cases will be prepared for early trial dates, to help the parties gauge how juries are likely to respond to certain evidence and testimony about hearing damage from Tepezza that will be repeated throughout various cases in the litigation.

If no Tepezza settlement agreement or other resolution is reached during the MDL pretrial proceedings, each individual claim may later be remanded back to the U.S. District Court where it was originally filed for trial.

Image Credit: |


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted 2 days ago)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 4 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.